Published in Psychopharmacology (Berl) on May 17, 2012
Neuropeptidergic signaling partitions arousal behaviors in zebrafish. J Neurosci (2014) 1.14
Orexin/hypocretin system modulates amygdala-dependent threat learning through the locus coeruleus. Proc Natl Acad Sci U S A (2013) 1.01
Orexin/hypocretin role in reward: implications for opioid and other addictions. Br J Pharmacol (2014) 0.92
The hypocretin/orexin system mediates the extinction of fear memories. Neuropsychopharmacology (2014) 0.88
Anxiolytic function of the orexin 2/hypocretin A receptor in the basolateral amygdala. Psychoneuroendocrinology (2013) 0.84
A selective orexin-1 receptor antagonist attenuates stress-induced hyperarousal without hypnotic effects. J Pharmacol Exp Ther (2015) 0.83
The selective orexin receptor 1 antagonist ACT-335827 in a rat model of diet-induced obesity associated with metabolic syndrome. Front Pharmacol (2013) 0.83
Differential actions of orexin receptors in brainstem cholinergic and monoaminergic neurons revealed by receptor knockouts: implications for orexinergic signaling in arousal and narcolepsy. Front Neurosci (2013) 0.82
Orexin neuropeptides contribute to the development and persistence of generalized avoidance behavior in the rat. Psychopharmacology (Berl) (2014) 0.79
Blocking of orexin receptors in the paraventricular nucleus of the thalamus has no effect on the expression of conditioned fear in rats. Front Behav Neurosci (2015) 0.78
Orexin/hypocretin receptor 1 signaling mediates Pavlovian cue-food conditioning and extinction. Physiol Behav (2016) 0.76
Evaluation of JNJ-54717793 a Novel Brain Penetrant Selective Orexin 1 Receptor Antagonist in Two Rat Models of Panic Attack Provocation. Front Pharmacol (2017) 0.75
Activation of orexin/hypocretin neurons is associated with individual differences in cued fear extinction. Physiol Behav (2016) 0.75
Pancreatic polypeptide and its central Y4 receptors are essential for cued fear extinction and permanent suppression of fear. Br J Pharmacol (2016) 0.75
Neurons containing hypocretin (orexin) project to multiple neuronal systems. J Neurosci (1998) 9.88
Differential expression of orexin receptors 1 and 2 in the rat brain. J Comp Neurol (2001) 4.88
The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness. Nat Rev Neurosci (2007) 4.46
The neuroanatomical and neurochemical basis of conditioned fear. Neurosci Biobehav Rev (1999) 3.66
Promotion of sleep by targeting the orexin system in rats, dogs and humans. Nat Med (2007) 3.25
A review of the modulation of the startle reflex by affective states and its application in psychiatry. Clin Neurophysiol (2003) 2.91
Double dissociation between the involvement of the bed nucleus of the stria terminalis and the central nucleus of the amygdala in startle increases produced by conditioned versus unconditioned fear. J Neurosci (1997) 2.90
Afferents to the orexin neurons of the rat brain. J Comp Neurol (2006) 2.57
Attenuated defense response and low basal blood pressure in orexin knockout mice. Am J Physiol Regul Integr Comp Physiol (2003) 2.45
Fear-potentiated startle conditioning to explicit and contextual cues in Gulf War veterans with posttraumatic stress disorder. J Abnorm Psychol (1999) 2.34
Models and mechanisms of anxiety: evidence from startle studies. Psychopharmacology (Berl) (2007) 2.18
Input of orexin/hypocretin neurons revealed by a genetically encoded tracer in mice. Neuron (2005) 2.11
Overlapping distributions of orexin/hypocretin- and dopamine-beta-hydroxylase immunoreactive fibers in rat brain regions mediating arousal, motivation, and stress. J Comp Neurol (2003) 1.98
Generalization of conditioned fear-potentiated startle in humans: experimental validation and clinical relevance. Behav Res Ther (2008) 1.84
Receptors for the age of anxiety: pharmacology of the benzodiazepines. Science (1980) 1.76
Gene expression and protein distribution of the orexin-1 receptor in the rat brain and spinal cord. Neuroscience (2001) 1.69
A key role for orexin in panic anxiety. Nat Med (2009) 1.63
Conditioned fear as revealed by magnitude of startle response to an auditory stimulus. J Exp Psychol (1951) 1.60
Baseline and fear-potentiated startle in panic disorder patients. Biol Psychiatry (1994) 1.49
Anxiogenic effects of high illumination levels assessed with the acoustic startle response in rats. Biol Psychiatry (1997) 1.40
Fear-potentiated startle in posttraumatic stress disorder. Biol Psychiatry (1995) 1.38
A single dose of the selective serotonin reuptake inhibitor citalopram exacerbates anxiety in humans: a fear-potentiated startle study. Neuropsychopharmacology (2006) 1.37
Acute selective serotonin reuptake inhibitors increase conditioned fear expression: blockade with a 5-HT(2C) receptor antagonist. Biol Psychiatry (2007) 1.36
Differential distribution and regulation of OX1 and OX2 orexin/hypocretin receptor messenger RNA in the brain upon fasting. Horm Behav (2000) 1.34
Protein distribution of the orexin-2 receptor in the rat central nervous system. Regul Pept (2002) 1.28
Hypocretin/orexin contributes to the expression of some but not all forms of stress and arousal. Eur J Neurosci (2009) 1.22
Antidepressant-induced jitteriness/anxiety syndrome: systematic review. Br J Psychiatry (2009) 1.20
Darkness facilitates the acoustic startle reflex in humans. Biol Psychiatry (1997) 1.18
Fear-potentiated startle using an auditory conditioned stimulus: effect of lesions of the amygdala. Physiol Behav (1987) 1.17
Orexins in the paraventricular nucleus of the thalamus mediate anxiety-like responses in rats. Psychopharmacology (Berl) (2010) 1.14
Fear-potentiated startle and posttraumatic stress symptoms in urban police officers. J Trauma Stress (2003) 1.09
Orexin-A (hypocretin-1) is possibly involved in generation of anxiety-like behavior. Brain Res (2005) 1.09
Modulation of fear-potentiated startle and vocalizations in juvenile rhesus monkeys by morphine, diazepam, and buspirone. Biol Psychiatry (2006) 1.05
Excitatory action of hypocretin/orexin on neurons of the central medial amygdala. Neuroscience (2006) 1.04
Hcrtr1 and 2 signaling differentially regulates depression-like behaviors. Behav Brain Res (2011) 1.01
Oxytocin reduces background anxiety in a fear-potentiated startle paradigm. Neuropsychopharmacology (2010) 1.00
GABA-A and 5-HT1A receptor agonists block expression of fear-potentiated startle in mice. Neuropsychopharmacology (2002) 1.00
Orexin A in rat rostral ventrolateral medulla is pressor, sympatho-excitatory, increases barosensitivity and attenuates the somato-sympathetic reflex. Br J Pharmacol (2012) 1.00
Orexins in the regulation of the hypothalamic-pituitary-adrenal axis. Pharmacol Rev (2006) 0.96
Diazepam and flurazepam: effects on conditioned fear as measured with the potentiated startle paradigm. Psychopharmacology (Berl) (1979) 0.95
Orexinergic innervation of the extended amygdala and basal ganglia in the rat. Brain Struct Funct (2011) 0.94
Buspirone: review of its pharmacology and current perspectives on its mechanism of action. Am J Med (1986) 0.94
Activation of the orexin 1 receptor is a critical component of CO2-mediated anxiety and hypertension but not bradycardia. Neuropsychopharmacology (2012) 0.93
Activation of orexin neurons in dorsomedial/perifornical hypothalamus and antidepressant reversal in a rodent model of depression. Neuropharmacology (2011) 0.90
Orexin neurons in the hypothalamus mediate cardiorespiratory responses induced by disinhibition of the amygdala and bed nucleus of the stria terminalis. Brain Res (2009) 0.90
Blockade of potentiated startle responding in rats by 5-hydroxytryptamine1A receptor ligands. Eur J Pharmacol (1988) 0.89
Reduced amygdala activity during aversive conditioning in human narcolepsy. Ann Neurol (2010) 0.89
Anxiolytic effects of buspirone and gepirone in the fear-potentiated startle paradigm. Psychopharmacology (Berl) (1988) 0.88
Discovery process and pharmacological characterization of a novel dual orexin 1 and orexin 2 receptor antagonist useful for treatment of sleep disorders. Bioorg Med Chem Lett (2011) 0.86
Effects of substance P in the amygdala, ventromedial hypothalamus, and periaqueductal gray on fear-potentiated startle. Neuropsychopharmacology (2008) 0.86
Social approach-avoidance behavior of a high-anxiety strain of rats: effects of benzodiazepine receptor ligands. Psychopharmacology (Berl) (2005) 0.86
Differential effects of the dual orexin receptor antagonist almorexant and the GABA(A)-α1 receptor modulator zolpidem, alone or combined with ethanol, on motor performance in the rat. Neuropsychopharmacology (2010) 0.85
Orexins: a role in medullary sympathetic outflow. Regul Pept (2000) 0.85
Intact learning and memory in rats following treatment with the dual orexin receptor antagonist almorexant. Psychopharmacology (Berl) (2010) 0.84
Amygdala dysfunction in narcolepsy-cataplexy. J Sleep Res (2007) 0.84
State-dependent central chemoreception: a role of orexin. Respir Physiol Neurobiol (2010) 0.82
Amygdalar orexinergic-GABAergic interactions regulate anxiety behaviors of the Syrian golden hamster. Behav Brain Res (2010) 0.81
Favoured genetic background for testing anxiolytics in the fear-potentiated and light-enhanced startle paradigms in the rat. Behav Brain Res (2011) 0.80
Evidence for a role of inhibition of orexinergic neurons in the anxiolytic and sedative effects of diazepam: A c-Fos study. Pharmacol Biochem Behav (2011) 0.79
Fear-potentiated startle response is remarkably similar in two laboratories. Psychopharmacology (Berl) (1996) 0.79
Association between major mood disorders and the hypocretin receptor 1 gene. J Affect Disord (2010) 0.79
Amygdaloid axons innervate melanin-concentrating hormone- and orexin-containing neurons in the mouse lateral hypothalamus. Brain Res (2009) 0.79
Potentiation of the acoustic startle response by a conditioned stimulus paired with acoustic startle stimulus in rats. J Exp Psychol Anim Behav Process (1990) 0.78
Effects of buspirone and alprazolam treatment on the startle-potentiated startle response. Depress Anxiety (2004) 0.78
Diazepam blocks fear-enhanced startle elicited electrically from the brainstem. Physiol Behav (1984) 0.77
Effects of midazolam, DMCM and lindane on potentiated startle in the rat. Psychopharmacology (Berl) (1989) 0.76
Acoustic startle, conditioned startle potentiation and the effects of 8-OH-DPAT and buspirone in rats selectively bred for differences in 8-OH-DPAT-induced hypothermia. Behav Pharmacol (2001) 0.75
Preclinical evidence that sildenafil and vardenafil activate chloride transport in cystic fibrosis. Am J Respir Crit Care Med (2007) 2.18
Orexin receptor antagonists: a new concept in CNS disorders? ChemMedChem (2010) 1.00
Biomedical application of orexin/hypocretin receptor ligands in neuroscience. J Med Chem (2009) 0.98
Discovery and characterization of ACT-335827, an orally available, brain penetrant orexin receptor type 1 selective antagonist. ChemMedChem (2013) 0.96
Differential effects of the dual orexin receptor antagonist almorexant and the GABA(A)-α1 receptor modulator zolpidem, alone or combined with ethanol, on motor performance in the rat. Neuropsychopharmacology (2010) 0.85
N-Glycine-sulfonamides as potent dual orexin 1/orexin 2 receptor antagonists. Bioorg Med Chem Lett (2008) 0.83
Favoured genetic background for testing anxiolytics in the fear-potentiated and light-enhanced startle paradigms in the rat. Behav Brain Res (2011) 0.80
Examining the role of endogenous orexins in hypothalamus-pituitary-adrenal axis endocrine function using transient dual orexin receptor antagonism in the rat. Psychoneuroendocrinology (2012) 0.80
Orexin neuropeptides contribute to the development and persistence of generalized avoidance behavior in the rat. Psychopharmacology (Berl) (2014) 0.79
Structure-activity relationship studies and sleep-promoting activity of novel 1-chloro-5,6,7,8-tetrahydroimidazo[1,5-a]pyrazine derivatives as dual orexin receptor antagonists. Part 2. Bioorg Med Chem Lett (2013) 0.77
The dual orexin receptor antagonist almorexant, alone and in combination with morphine, cocaine and amphetamine, on conditioned place preference and locomotor sensitization in the rat. Int J Neuropsychopharmacol (2012) 0.76
Structure-activity relationship, biological, and pharmacological characterization of the proline sulfonamide ACT-462206: a potent, brain-penetrant dual orexin 1/orexin 2 receptor antagonist. ChemMedChem (2014) 0.75
Novel pyrazolo-tetrahydropyridines as potent orexin receptor antagonists. Bioorg Med Chem Lett (2010) 0.75
Synthesis, structure-activity relationship studies, and identification of novel 5,6,7,8-tetrahydroimidazo[1,5-a]pyrazine derivatives as dual orexin receptor antagonists. Part 1. Bioorg Med Chem Lett (2013) 0.75